Science translational medicine · 2024
Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Le Moal Emmeran, Liu Yuguo, Collerette-Tremblay Jasmin, Dumontier Simon, Fabre Paul, Molina Thomas, Dort Junio, Orfi Zakaria, Denault Nicolas, Boutin Joël, Michaud Joris, Giguère Hugo, Desroches Alexandre, Trân Kien, Ellezam Benjamin, Vézina François, Bedard Sonia, Raynaud Catherine, Balg Frederic, Sarret Philippe, Boudreault Pierre-Luc, Scott Michelle S, Denault Jean-Bernard, Marsault Eric, Feige Jerome N, Auger-Messier Mannix, Dumont Nicolas A, Bentzinger C Florian
Аннотация
Impaired skeletal muscle stem cell (MuSC) function has long been suspected to contribute to the pathogenesis of muscular dystrophy (MD). Here, we showed that defects in the endothelial cell (EC) compartment of the vascular stem cell niche in mouse models of Duchenne MD, laminin α2-related MD, and collagen VI-related myopathy were associated with inefficient mobilization of MuSCs after tissue damage. Using chemoinformatic analysis, we identified the 13-amino acid form of the peptide hormone apelin (AP-13) as a candidate for systemic stimulation of skeletal muscle ECs. Systemic administration of AP-13 using osmotic pumps generated a pro-proliferative EC-rich niche that supported MuSC function through angiocrine factors and markedly improved tissue regeneration and muscle strength in all three dystrophic mouse models. Moreover, EC-specific knockout of the apelin receptor led to regenerative defects that phenocopied key pathological features of MD, including vascular defects, fibrosis, muscle fiber necrosis, impaired MuSC function, and reduced force generation. Together, these studies provide in vivo proof of concept that enhancing endogenous skeletal muscle repair by targeting the vascular niche is a viable therapeutic avenue for MD and characterized AP-13 as a candidate for further study for the systemic treatment of MuSC dysfunction.